The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
Open accessPublished version of a preprint
Abstract
Tumor protein p53 (TP53) is the most frequently mutated gene in cancer 1,2. In patients with myelodysplastic syndromes (MDS), TP53 mutations are associated with high-risk disease 3,4, rapid transformation to acute myeloid leukemia (AML)5, resistance to conventional therapies 6-8 and dismal outcomes 9. Consistent with the tumor-suppressive role of TP53, patients harbor both mono- and biallelic mutations 10. However, the biological and clinical implications of TP53 allelic state have not been fully investigated in MDS or any other cancer type. We analyzed 3,324 patients with MDS for TP53 mutations and allelic imbalances and delineated two subsets of patients with distinct phenotypes and outcomes. One-third of TP53-mutated patients had monoallelic mutations whereas two-thirds had multiple hits (multi-hit) consistent with biallelic targeting. Established associations with complex karyotype, few co-occurring mutations, high-risk presentation and poor outcomes were specific to multi-hit patients only. TP53 multi-hit state predicted risk of death and leukemic transformation independently of the Revised International Prognostic Scoring System (IPSS-R)11. Surprisingly, monoallelic patients did not differ from TP53 wild-type patients in outcomes and response to therapy. This study shows that consideration of TP53 allelic state is critical for diagnostic and prognostic precision in MDS as well as in future correlative studies of treatment response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Treatment outcomes for patients with TP53 mutations are poor with available therapies.8-12”
From Eprenetapopt (APR-246) and Azacitidine in TP53 -Mutant Myelodysplastic Syndromes (2021) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The TP53 mutation burden (ie, high variant allele frequency [VAF], concurrent complex karyotype, and/or multihit state) is integrally linked to inferior survival with median OS of 6-8 months.8-10,12”
From Eprenetapopt (APR-246) and Azacitidine in TP53 -Mutant Myelodysplastic Syndromes (2021) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, remissions in TP53-mutant patients are brief with a median overall survival (OS) ranging from 5 to 12 months,8,9,12,13,15-17”
From Eprenetapopt (APR-246) and Azacitidine in TP53 -Mutant Myelodysplastic Syndromes (2021) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“TP53 gene mutations (mTP53) represent a distinct molecular cohort with poor outcomes.”
From Long‐term follow‐up and combined Phase 2 results of eprenetapopt and azacitidine in patients with TP53 mutant MDS/AML (2025) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“TP53 gene mutations (mTP53) are found in up to 20% of myelodysplastic syndromes/neoplasms (MDS) or acute myeloid leukemia (AML) pts and 30%–40% of therapy‐related (TR) MDS/AML cases”
From Long‐term follow‐up and combined Phase 2 results of eprenetapopt and azacitidine in patients with TP53 mutant MDS/AML (2025) · cites this paper as [3]
Experimental — accuracy not yet measured
The cited source says what the claim attributes to it.
In the citing paper
“Specifically, mTP53 patients with a high variant allele frequency (VAF; i.e., >20%–23%), biallelic state, and/or complex karyotype (CK) have particularly poor risk.”
From Long‐term follow‐up and combined Phase 2 results of eprenetapopt and azacitidine in patients with TP53 mutant MDS/AML (2025) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“Despite the known dominant negative and/or gain of function effect of certain TP53 mutations28,42, loss of the TP53-WT allele, a genetic event associated with a particularly dismal prognosis2, confers an additional fitness advantage to TP53-sAML LSCs.”
From Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolution (2023) · cites this paper as [2]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Fast and accurate long-read alignment with Burrows-Wheeler transform.
Li, H., & Durbin, R. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp698 · Cited by 12,063
The mutational constraint spectrum quantified from variation in 141,456 humans
Karczewski, K. J., Francioli, L. C., Tiao, G., Cummings, B. B., Alföldi, J., Wang, Q., Collins, R. L., Laricchia, K. M., Ganna, A., Birnbaum, D. P., et al. (2020) · Nature · doi:10.1038/s41586-020-2308-7 · Cited by 9,434
Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration
Thorvaldsdottir, H., Robinson, J. T., & Mesirov, J. P. (2013) · Briefings in Bioinformatics · doi:10.1093/bib/bbs017 · Cited by 9,049
A New Initiative on Precision Medicine
Collins, F. S., & Varmus, H. (2015) · New England Journal of Medicine · doi:10.1056/nejmp1500523 · Cited by 5,202
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Cibulskis, K., Lawrence, M. S., Carter, S. L., Sivachenko, A., Jaffe, D. B., Sougnez, C. L., Gabriel, S., Meyerson, M. M., Lander, E. S., & Getz, G. A. (2013) · Nature Biotechnology · doi:10.1038/nbt.2514 · Cited by 4,965
COSMIC: the Catalogue Of Somatic Mutations In Cancer
Tate, J. G., Bamford, S., Jubb, H. C., Sondka, Z., Beare, D. M., Bindal, N., Boutselakis, H., Cole, C. G., Creatore, C., Dawson, E., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1015 · Cited by 4,867
Mutational landscape and significance across 12 major cancer types
Kandoth, C., McLellan, M. D., Vandin, F., Ye, K., Niu, B., Lu, C., Xie, M., Zhang, Q., McMichael, J. F., Wyczalkowski, M. A., et al. (2013) · Nature · doi:10.1038/nature12634 · Cited by 4,419
Genomic classification and prognosis in acute myeloid leukemia
Papaemmanuil, E., Gerstung, M., Bullinger, L., Gaidzik, V. I., Paschka, P., Roberts, N. D., Potter, N. E., Heuser, M., Thol, F., Bolli, N., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1516192 · Cited by 4,350
Self-citation
Cited by
Sorted by citations
Items 301–400 of 648
Porta, M. G. D., Bewersdorf, J. P., Wang, Y., & Hasserjian, R. P. (2024) · Histopathology · doi:10.1111/his.15353 · Cited by 8
Self-citationLiquori, A., Lesende‐Rodriguez, I., Palomo, L., Avetisyan, G., Ibáñez, M., González-Romero, E., Boluda-Navarro, M., Morote-Faubel, M., García-Ruiz, C., Martínez-Valiente, C., et al. (2021) · Cancers · doi:10.3390/cancers13081947 · Cited by 8
Self-citationWang, C., & Sallman, D. A. (2022) · The Cancer Journal · doi:10.1097/ppo.0000000000000569 · Cited by 8
Lee, W. Y., Gutierrez-Lanz, E., Xiao, H., McClintock, D., Chan, M. P., Bixby, D. L., & Shao, L. (2022) · Genes Chromosomes and Cancer · doi:10.1002/gcc.23027 · Cited by 8
Kato, H., Maezawa, Y., Nishijima, D., Iwamoto, E., Takeda, J., Kanamori, T., Yamaga, M., Mishina, T., Takeda, Y., Izumi, S., et al. (2022) · Experimental Hematology · doi:10.1016/j.exphem.2022.02.005 · Cited by 8
Self-citationNajima, Y., Tachibana, T., Takeda, Y., Koda, Y., Aoyama, Y., Toya, T., Igarashi, A., Tanaka, M., Sakaida, E., Abe, R., et al. (2022) · Annals of Hematology · doi:10.1007/s00277-022-04981-x · Cited by 8
Impact of the International Consensus Classification of myelodysplastic syndromes
Zhang, Y., Wu, J., Xu, Z., Qin, T., Qu, S., Pan, L., Wang, H., Sun, Q., Li, C., Jia, Y., et al. (2022) · British Journal of Haematology · doi:10.1111/bjh.18628 · Cited by 8
Self-citationImpact of Frailty on Health Care Resource Utilization and Costs of Care in Myelodysplastic Syndromes
Mozessohn, L., Li, Q., Liu, N., Leber, B. F., Khalaf, D., Sabloff, M., Christou, G., Yee, K. W. L., Chodirker, L., Parmentier, A., et al. (2023) · JCO Oncology Practice · doi:10.1200/op.22.00668 · Cited by 8
TP53 and RB1 alterations characterize poor prognostic subgroups in pediatric acute myeloid leukemia
Hara, Y., Shiba, N., Yoshida, K., Yamato, G., Kaburagi, T., Shiraishi, Y., Ohki, K., Shiozawa, Y., Kawamura, M., Kawasaki, H., et al. (2023) · Genes Chromosomes and Cancer · doi:10.1002/gcc.23147 · Cited by 8
Self-citationBoyd, R. J., Murry, J. B., Morsberger, L. A., Klausner, M., Chen, S., Gocke, C. D., McCallion, A. S., & Zou, Y. S. (2023) · Cancers · doi:10.3390/cancers15225439 · Cited by 8
Fifth edition WHO classification: myeloid neoplasms
Chen, X., Patkar, N. V., Tembhare, P. R., Subramanian, P. G., Yeung, C., Kanagal‐Shamanna, R., Gujral, S., Wood, B. L., & Naresh, K. N. (2025) · Journal of Clinical Pathology · doi:10.1136/jcp-2024-210022 · Cited by 7
Molecular and Clinical Insights into TP53-Mutated MDS and AML
Georgantzinos, E., & Karantanos, T. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262210818 · Cited by 7
Azevedo, R. S., Jabbour, E. J., Kantarjian, H. M., Lavu, S., Loghavi, S., Jain, N., Sasaki, K., Garris, R. S., Takahashi, K., Ravandi, F., et al. (2025) · Blood · doi:10.1182/blood.2025030498 · Cited by 7
Molecular-Based Ecosystem to Improve Personalized Medicine in Chronic Myelomonocytic Leukemia
Lanino, L., Hunter, A. M., Gagelmann, N., Robin, M., Dall’Olio, D., Flamigni, A., Sala, C., Gurnari, C., Wang, Y., Pleyer, L., et al. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-25-02116 · Cited by 7
Self-citationUppal, M., Bhinder, B., Marderstein, A. R., Batlevi, C. L., Falchi, L., Hamlin, P., Horwitz, S. M., Kumar, A. A., Noy, A., Zelenetz, A. D., et al. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-25-01928 · Cited by 7
Molecular-Targeted Therapy for Tumor-Agnostic Mutations in Acute Myeloid Leukemia
Arai, H., Minami, Y., Chi, S., Utsu, Y., Masuda, S., & Aotsuka, N. (2022) · Biomedicines · doi:10.3390/biomedicines10123008 · Cited by 7
The prognostic role of lymphocyte to monocyte ratio (LMR) in patients with Myelodysplastic Neoplasms
Lu, C., Chen, Q., Li, J., Wang, C., & Yu, L. (2023) · Hematology · doi:10.1080/16078454.2023.2210929 · Cited by 7
Management of Patients with Lower-Risk Myelodysplastic Neoplasms (MDS)
Lucero, J. A., Al-Harbi, S., & Yee, K. W. L. (2023) · Current Oncology · doi:10.3390/curroncol30070459 · Cited by 7
Xue, Y., Xia, X., Liu, X., Zheng, Y., Gu, H., & Wang, X. (2024) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2902086 · Cited by 7
Creignou, M., Bernard, E., Gasparini, A., Tranberg, A., Todisco, G., Moura, P. L., Ejerblad, E., Nilsson, L., Garelius, H. G., Antunović, P., et al. (2024) · Journal of Internal Medicine · doi:10.1111/joim.13790 · Cited by 7
Self-citationSingle Cell Detection of the p53 Protein by Mass Cytometry
Fagerholt, O. H. E., Hellesøy, M., Gullaksen, S., & Gjertsen, B. T. (2020) · Cancers · doi:10.3390/cancers12123699 · Cited by 7
Shallis, R. M., Stahl, M. F., Bewersdorf, J. P., & Zeidan, A. M. (2021) · Hemato · doi:10.3390/hemato2040051 · Cited by 7
Molecular landscape of myelodysplastic neoplasms in disease classification and prognostication
Maggioni, G., & Porta, M. G. D. (2022) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000752 · Cited by 7
Morales, M. L., & Ferrer‐Marín, F. (2023) · Cancers · doi:10.3390/cancers15041348 · Cited by 7
Monitoring molecular changes in the management of myelodysplastic syndromes
Duployez, N., & Preudhomme, C. (2024) · British Journal of Haematology · doi:10.1111/bjh.19614 · Cited by 7
Warnstorf, D., Bawadi, R., Schienke, A., Strasser, R., Schmidt, G., Illig, T., Tauscher, M., Thol, F. R., Heuser, M., Steinemann, D., et al. (2021) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22938 · Cited by 7
Self-citationMolecular Drivers of Myelodysplastic Neoplasms (MDS)—Classification and Prognostic Relevance
Hoff, F. W., & Madanat, Y. F. (2023) · Cells · doi:10.3390/cells12040627 · Cited by 8
Zhang, C., Wen, R., Wu, G.-C., Li, G., Wu, X., Guo, Y., & Yang, Z. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2023.1301236 · Cited by 6
Zhao, Y., Cao, W., Shi, J., Cao, Y., Luo, Y., Luo, Y., Ouyang, G., Chen, L., Lan, J., Song, X., et al. (2025) · Leukemia · doi:10.1038/s41375-025-02672-w · Cited by 6
How I Manage Transplant Ineligible Patients with Myelodysplastic Neoplasms
Gurnari, C., Xie, Z., & Zeidan, A. M. (2022) · Clinical Hematology International · doi:10.1007/s44228-022-00024-4 · Cited by 6
Myelodysplastic syndromes del(5q): Pathogenesis and its therapeutic implications
Bruzzese, A., Martino, E. A., Mendicino, F., Lucia, E., Olivito, V., Capodanno, I., Neri, A., Morabito, F., Vigna, E., & Gentile, M. (2024) · European Journal Of Haematology · doi:10.1111/ejh.14181 · Cited by 6
Yupanki, M. L., Andreoli, V., Rivello, H. G., Bender, A., Catalán, A. I., Rahhal, M., Delamer, R., Asinari, M., Orgueira, A. M., Castro, M. B., et al. (2024) · Annals of Laboratory Medicine · doi:10.3343/alm.2024.0089 · Cited by 6
Bidikian, A., Bewersdorf, J. P., Shallis, R. M., Getz, T. M., Stempel, J. M., Kewan, T. Z., Stahl, M. F., & Zeidan, A. M. (2024) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2024.2414071 · Cited by 6
Andricovich, J., Lap, C. J. G., & Tzatsos, A. (2025) · Blood · doi:10.1182/blood.2024026417 · Cited by 6
Pathophysiology of Myelodysplastic Syndromes
Fontenay, M., Farhat, B., & Boussaid, I. (2021) · Hemato · doi:10.3390/hemato2030030 · Cited by 6
Self-citationUpdates in molecular genetics of therapy-related myeloid neoplasms
Cantu, M. D. (2023) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2023.04.001 · Cited by 6
Guide to the Diagnosis of Myeloid Neoplasms: A Bone Marrow Pathology Group Approach
Foucar, K. K., Bagg, A., Bueso-Ramos, C., George, T. I., Hasserjian, R. P., Hsi, E. D., Orazi, A., Tam, W., Wang, S. A., Weinberg, O. K., et al. (2023) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqad069 · Cited by 6
Self-citationTHERAPY-RELATED MYELOID NEOPLASMS: PREDISPOSITION AND CLONAL EVOLUTION
Fabiani, E., Falconi, G., Cristiano, A., Hajrullaj, H., Falconi, G., Leone, G. G. M., & Voso, M. T. (2023) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2023.064 · Cited by 6
Self-citationBravo, G. M., Jabbour, E. J., Borthakur, G. M., Kadia, T. M., Ravandi, F., Chien, K. S., Pemmaraju, N., Hammond, D. E., Dong, X. Q., Huang, X., et al. (2023) · British Journal of Haematology · doi:10.1111/bjh.19193 · Cited by 6
A Brief Overview of the Molecular Landscape of Myelodysplastic Neoplasms
Abdulbaki, R., & Pullarkat, S. T. (2024) · Current Oncology · doi:10.3390/curroncol31050175 · Cited by 6
Marumo, A., Nagata, Y., Fujioka, M., Kurosawa, S., Najima, Y., Sakaida, E., Doki, N., Fukushima, K., Ota, S., Shono, K., et al. (2024) · Cytotherapy · doi:10.1016/j.jcyt.2024.09.006 · Cited by 6
Self-citationPrognosis in Myelodysplastic Syndromes: The Clinical Challenge of Genomic Integration
Chen‐Liang, T. H. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10102052 · Cited by 6
Yu, J. B., Du, Y., Jalil, A., Ahmed, Z., Mori, S., Patel, R. D., Varela, J. C., & Chang, C.-C. (2021) · Leukemia Research · doi:10.1016/j.leukres.2021.106701 · Cited by 6
Menendez-Gonzalez, J. B., & Rodrigues, N. P. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-1924-7_5 · Cited by 6
Zhang, W., Huang, C., Liu, R., Zhang, H., Li, W., Yin, S., Wang, L., Liu, W., & Liu, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.983934 · Cited by 6
Cavalcante, G., Borges, D. D. P., de Oliveira, R. T. G., Furtado, C. L. M., Alves, A. P. N. N., SOUSA, A. M. D., de Paula, D. S., Filho, F. D. R., Magalhães, S. M. M., Ribeiro, H. L., et al. (2020) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2020-207131 · Cited by 6
Self-citationUnmet Horizons: Assessing the Challenges in the Treatment of TP53-Mutated Acute Myeloid Leukemia
Stafylidis, C., Vlachopoulou, D., Kontandreopoulou, C., & Diamantopoulos, P. T. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13041082 · Cited by 6
Pourhassan, H., Tinajero, J., Ma, H., Jackson, R., Pillai, R. K., Ngo, D., Agrawal, V., Koller, P., Ball, B. J., Blackmon, A. L., et al. (2025) · British Journal of Haematology · doi:10.1111/bjh.20260 · Cited by 5
Garcia, J. S., Kim, H. T., Murdock, H. M., Bosch‐Vilaseca, A., Panaro, K. M., Lim, F., Fiorilla, J., Auriemma, E., Brock, J., Gooptu, M., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025018631 · Cited by 5
Hernández, N. T., Mora, E., García-Ruiz, C., Diaz-González, A., Avetisyan, G., Martı́nez, D., Berenguer-Rubio, A., Botella, C., Benet, C., Gómez-Catalán, I., et al. (2026) · npj Precision Oncology · doi:10.1038/s41698-025-01258-0 · Cited by 5
Self-citationQiu, G., Yin, Z., Lu, X., Xue, R., Tang, S., Zhou, C., Huang, X., Fan, M., Ai, Y., Xiang, G., et al. (2026) · Experimental Hematology and Oncology · doi:10.1186/s40164-026-00751-x · Cited by 5
Self-citationTP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA
Testa, U., Castelli, G., & Pelosi, E. (2023) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2023.038 · Cited by 6
Haploinsufficient Transcription Factors in Myeloid Neoplasms
Martinez, T. C., & McNerney, M. E. (2023) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-051222-013421 · Cited by 5
Validation of independent prognostic significance of blast count in a large cohort of MDS patients
Amri, R. A., Baloda, V., Monaghan, S. A., Rosado, F., Moore, E. M., Rea, B. A., Djokic, M., Aggarwal, N., Yatsenko, S. A., & Bailey, N. G. (2024) · Leukemia · doi:10.1038/s41375-024-02348-x · Cited by 5
How we diagnose Myelodysplastic syndromes
Oster, H. S., & Mittelman, M. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1415101 · Cited by 5
Transplant options and outcomes for TP53 myeloid disease
Fernandez, H. F., & Mishra, A. (2024) · Hematology · doi:10.1182/hematology.2024000558 · Cited by 5
Rombaut, D., Sandmann, S., Tekath, T., Crouch, S., de Graaf, A. O., Smith, A. G., Painter, D., Kosmider, O., Tobiasson, M., Lennartsson, A., et al. (2025) · HemaSphere · doi:10.1002/hem3.70073 · Cited by 6
Self-citationPrecision Medicine in Myeloid Neoplasia: Challenges and Opportunities
Hochman, M. J., Muñiz, J. P., & Papadantonakis, N. (2025) · Journal of Personalized Medicine · doi:10.3390/jpm15020049 · Cited by 5
Two ways to complex karyotype in MDS—the role of del(5q) and TP53
Huber, S., Hütter, S., Baer, C. R., Meggendorfer, M., Hoermann, G., Kern, W., Haferlach, T., & Haferlach, C. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01305-w · Cited by 5
Madarász, K., Mótyán, J. A., Bedekovics, J., Miltényi, Z., Újfalusi, A., Méhes, G., & Mokánszki, A. (2022) · Cells · doi:10.3390/cells11213475 · Cited by 5
Novel high–risk acute myeloid leukemia subgroup with ERG amplification and Biallelic loss of TP53
Schandl, C. A., Mazzoni, S. A., Znoyko, I. Y., Nahhas, G. J., Chung, D., Ding, Y., Hess, B. T., & Wolff, D. J. (2023) · Cancer Genetics · doi:10.1016/j.cancergen.2023.01.004 · Cited by 5
Zheng, G., Li, P., Zhang, X., & Pan, Z. (2022) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000748 · Cited by 5
Prognostic and clinicopathological value of CDK12 mutation in prostate cancer: a meta-analysis
Zhang, W., Zhou, L., & Di, J. (2023) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2023.2168647 · Cited by 5
Cutler, C. S. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.24.00649 · Cited by 5
Nontransplant treatment approaches for myeloid neoplasm with mutated TP53
Mehta, A. K., & Konopleva, M. (2024) · Hematology · doi:10.1182/hematology.2024000557 · Cited by 5
Ball, S., Komrokji, R. S., & Sallman, D. A. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.2018579 · Cited by 5
Sanvisens, A., Ameijide, A., Carulla, M., & Marcos‐Gragera, R. (2021) · Medicina Clínica · doi:10.1016/j.medcli.2021.09.035 · Cited by 5
How low risk are low risk myelodysplastic syndromes?
Dezern, A. E., & Dalton, W. B. (2022) · Expert Review of Hematology · doi:10.1080/17474086.2022.2029698 · Cited by 5
Wang, X., Rampal, R. K., Hu, C. S., Tripodi, J., Farnoud, N. R., Petersen, B. E., Rossi, M. R., Patel, M. A., McGovern, E. M., Najfeld, V., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.156534 · Cited by 5
Self-citationWang, Y., Sun, Y., Xie, J., Hu, J., Liu, N., Chen, J., Li, B., Lan, S., Niu, J., Wang, L., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.928324 · Cited by 5
Self-citationTefferi, A., Singh, A., Gangat, N., Al‐Kali, A., Alkhateeb, H. B., Shah, M. V., Patnaik, M. M., Elliott, M. A., Hogan, W. J., Litzow, M. R., et al. (2022) · Haematologica · doi:10.3324/haematol.2022.281495 · Cited by 5
Hosono, N., Chi, S., Yamauchi, T., Fukushima, K., Shibayama, H., Katagiri, S., Gotoh, A., Eguchi, M., Morishita, T., Ogasawara, R., et al. (2023) · Cancer Science · doi:10.1111/cas.15746 · Cited by 5
Bachelot, A., Bouvier, A., Riou, J., Thépot, S., Giltat, A., Gomes, C. N., Paillassa, J., Jouanneau‐Courville, R., Renard, M., Beucher, A., et al. (2023) · American Journal of Hematology · doi:10.1002/ajh.26917 · Cited by 5
Rare Hematologic Malignancies and Pre-Leukemic Entities in Children and Adolescents Young Adults
Brown, A. M., & Batra, S. (2024) · Cancers · doi:10.3390/cancers16050997 · Cited by 5
Drugging the Master Regulator TP53 in Cancer: Mission Possible?
Blandino, G. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00192 · Cited by 5
Li, L., Müftüoğlu, M., Ayoub, E., Lv, J., Basyal, M., Zhao, R., Menon, P. S., Bidikian, A., Mak, P. Y., Nishida, Y., et al. (2025) · medRxiv · doi:10.1101/2025.04.11.25325281 · Cited by 5
Can we harmonize classification of TP53 mutant MDS/AML?
Sallman, D. A. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025016336 · Cited by 5
Pandora’s Box of AML: How TP53 Mutations Defy Therapy and Hint at New Hope
Olesinski, E. A., & Bhatt, S. (2025) · Biomedicines · doi:10.3390/biomedicines13123007 · Cited by 4
Myelodysplastic syndrome progress to acute myeloid leukemia: new insights and updates
Zhang, Y., Yan, L., Fan, C., Zhao, B., Chen, M., Hao, X., Zhu, G., Jia, Y., Xu, Y., & Shi, Z. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1769944 · Cited by 4
Self-citationPredicting outcome in higher-risk myelodysplastic syndrome patients treated with azacitidine
Bouchla, A., Thomopoulos, T. P., Papageorgiou, S. G., Apostolopoulou, C. A., Loucari, C. C., Mpazani, E., & Pappa, V. (2021) · Epigenomics · doi:10.2217/epi-2021-0124 · Cited by 4
Molecular Pathology of Myeloid Neoplasms
Sadigh, S., & Kim, A. S. (2021) · Surgical pathology clinics · doi:10.1016/j.path.2021.05.013 · Cited by 4
Sandmann, S., Behrens, Y. L., Davenport, C., Thol, F. R., Heuser, M., Dörfel, D., Löhr, F., Castrup, A., Steinemann, D., Varghese, J., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.888114 · Cited by 4
Self-citationThe Management of Low-Risk Myelodysplastic Syndromes—Current Standards and Recent Advances
Randall, M. P., & Dezern, A. E. (2023) · The Cancer Journal · doi:10.1097/ppo.0000000000000655 · Cited by 4
Luo, Y., Feng, X., Lang, W., Xu, W., Wang, W., Chen, M., Ye, L., Zhu, S., Wang, L., Zhou, X., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci172468 · Cited by 4
Evaluating targeted therapies in older patients with TP53 -mutated AML
Sabile, J. M. G., Swords, R. T., & Tyner, J. W. (2024) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2024.2344057 · Cited by 4
Variation characteristics and clinical significance of TP53 in patients with myeloid neoplasms
Ma, Q., Liu, Y., Zhao, H., Guo, Y., Sun, W., & Hu, R. (2024) · Hematology · doi:10.1080/16078454.2024.2387878 · Cited by 4
Overall survival in TP53-mutated AML and MDS
Puzo, C. J., Hager, K. M., Rinder, H. M., Weinberg, O. K., & Siddon, A. J. (2024) · Annals of Hematology · doi:10.1007/s00277-024-06054-7 · Cited by 4
Myelodysplastic Neoplasms (MDS): Pathogenesis and Therapeutic Prospects
Li, X., Zou, C., Xiang, X., Zhao, L., Chen, M., Yang, C., & Wu, Y. (2025) · Biomolecules · doi:10.3390/biom15060761 · Cited by 5
Park, H. S., Son, B. R., Shin, K. S., Byeon, S., Kim, H. K., Yang, Y., Jeong, Y., Han, H. S., Lee, K. H., & Kwon, J. (2021) · Acta Haematologica · doi:10.1159/000516793 · Cited by 4
Olíva, E. N., Latagliata, R., Sabattini, E., Mammì, C., Cuzzola, M., D’Errigo, M. G., Cannatà, M. C., Bova, I., Capodanno, I., Palumbo, G. A., et al. (2021) · Europe PMC (PubMed Central) · Cited by 4
Mądry, K., Drozd-Sokolowska, J. E., Lis, K., Budziszewska, B. K., Pogłódek, B., Machowicz, R., Subocz, E., Wiśniewska‐Piąty, K., Wróbel, T., Zaucha, J. M., et al. (2022) · Acta Haematologica Polonica · doi:10.5603/ahp.a2022.0001 · Cited by 4
Hu, C., & Wang, X. (2022) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2022.2070913 · Cited by 5
Therapeutic approaches for the management of higher risk myelodysplastic syndromes
Wang, C., & Sallman, D. A. (2022) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2022.2140287 · Cited by 4
Current State and Future Prospects of Diagnosis and Management of TP53-Mutated Myeloid Neoplasms
Venugopal, S., & Loghavi, S. (2023) · Pathobiology · doi:10.1159/000534566 · Cited by 4
Barabino, S. M. L., Citterio, E., & Ronchi, A. E. (2021) · Cancers · doi:10.3390/cancers13153753 · Cited by 4
Kansal, R. (2021) · Journal of Hematology Research · doi:10.12974/2312-5411.2021.08.3 · Cited by 5
High PD-L1 expression is associated with unfavorable clinical features in myelodysplastic neoplasms
Sampaio, L. R., Viana, M. D. A., de Oliveira, V. S., Ferreira, B. V., Melo, M. M. D. L., de Oliveira, R. T. G., Borges, D. D. P., Magalhãesa, S. M. M., & Pinheiro, R. F. (2023) · Hematology Transfusion and Cell Therapy · doi:10.1016/j.htct.2023.05.002 · Cited by 4
Self-citationGut Microbiota Composition Correlates with Disease Severity in Myelodysplastic Syndrome
Riello, G. B. C., da Silva, P. M., Oliveira, F. A. D. S., de Oliveira, R. T. G., da Silva, F. E. R., França, I. G. D. F., Miyajima, F., Melo, V. M. M., Pinheiro, R. F., & Macêdo, D. S. (2024) · International Journal of Hematology-Oncology and Stem Cell Research · doi:10.18502/ijhoscr.v18i2.15377 · Cited by 4
Self-citationMaslah, N., Diawara, Y., Sébert, M., Giraudier, S., Fenaux, P., & Cassinat, B. (2021) · British Journal of Haematology · doi:10.1111/bjh.17548 · Cited by 4
Self-citationA tale of two alleles: TP53 and transformation in MPNs
Brierley, C. K., & Psaila, B. (2022) · Blood · doi:10.1182/blood.2022016490 · Cited by 4
Metadata
- Authors
- Bernard, E., Nannya, Y., Hasserjian, R. P., Devlin, S. M., Tuechler, H., Medina-Martinez, J. S., Yoshizato, T., Shiozawa, Y., Saiki, R., Malcovati, L., Levine, M. F., Arango, J. E., Zhou, Y., Solé, F., Cargo, C. A., Haase, D., Creignou, M., Germing, U., Zhang, Y., Gundem, G., Sarian, A., van de Loosdrecht, A. A., Jädersten, M., Tobiasson, M., Kosmider, O., Follo, M. Y., Thol, F., Pinheiro, R. F., Santini, V., Kotsianidis, I., Boultwood, J., Santos, F. P. S., Schanz, J., Kasahara, S., Ishikawa, T., Tsurumi, H., Takaori-Kondo, A., Kiguchi, T., Polprasert, C., Bennett, J. M., Klimek, V. M., Savona, M. R., Belickova, M., Ganster, C., Palomo, L., Sanz, G., Ades, L., Della Porta, M. G., Elias, H. K., Smith, A. G., Werner, Y., Patel, M., Viale, A., Vanness, K., Neuberg, D. S., Stevenson, K. E., Menghrajani, K., Bolton, K. L., Fenaux, P., Pellagatti, A., Platzbecker, U., Heuser, M., Valent, P., Chiba, S., Miyazaki, Y., Finelli, C., Voso, M. T., Shih, L.-Y., Fontenay, M., Jansen, J. H., Cervera, J., Atsuta, Y., Gattermann, N., Ebert, B. L., Bejar, R., Greenberg, P. L., Cazzola, M., Hellström-Lindberg, E., Ogawa, S., & Papaemmanuil, E.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Kyoto University (JP)
- Massachusetts General Hospital (US)
- University of Pavia (IT)
- Josep Carreras Leukaemia Research Institute (ES)
- St James's University Hospital (GB)
- Universitätsmedizin Göttingen (DE)
- Karolinska University Hospital (SE)
- Heinrich Heine University Düsseldorf (DE)
- Université Paris Cité (FR)
- University of Bologna (IT)
- Medizinische Hochschule Hannover (DE)
- Universidade Federal do Ceará (BR)
- Azienda Ospedaliero-Universitaria Careggi (IT)
- University of Oxford (GB)
- Gifu Municipal Hospital (JP)
- Kobe City Medical Center General Hospital (JP)
- Gifu University (JP)
- Chugoku Central Hospital (JP)
- Chulalongkorn University (TH)
- University of Rochester Medicine (US)
- Vanderbilt University (US)
- Instituto de Salud Carlos III (ES)
- University of York (GB)
- Dana-Farber Cancer Institute (US)
- Hôpital Saint-Louis (FR)
- Leipzig University (DE)
- Ludwig Boltzmann Institute for Hematology and Oncology (AT)
- University of Tsukuba (JP)
- Nagasaki University (JP)
- IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola (IT)
- University of Rome Tor Vergata (IT)
- Chang Gung University (TW)
- Radboud University Medical Center (NL)
- Hospital Universitari i Politècnic La Fe (ES)
- The Japanese Data Center for Hematopoietic Cell Transplantation (JP)
- Howard Hughes Medical Institute (US)
- Moores Cancer Center (US)
- Stanford Cancer Institute (US)
- Corresponding author
- Papaemmanuil, Elli
- ORCID
- Bernard, Elsa
- Nannya, Yasuhito
- Hasserjian, Robert P.
- Devlin, Sean M.
- Tuechler, Heinz
- Medina-Martinez, Juan S.
- Yoshizato, Tetsuichi
- Saiki, Ryunosuke
- Malcovati, Luca
- Levine, Max F.
- Solé, Francesc
- Cargo, Catherine A.
- Creignou, Maria
- Germing, Ulrich
- Zhang, Yanming
- Gundem, Gunes
- Jädersten, Martin
- Tobiasson, Magnus
- Kosmider, Olivier
- Follo, Matilde Y.
- Thol, Felicitas
- Pinheiro, Ronald F.
- Santini, Valeria
- Boultwood, Jacqueline
- Schanz, Julie
- Kasahara, Senji
- Ishikawa, Takayuki
- Tsurumi, Hisashi
- Takaori-Kondo, Akifumi
- Kiguchi, Toru
- Polprasert, Chantana
- Bennett, John M.
- Savona, Michael R.
- Belickova, Monika
- Ganster, Christina
- Palomo, Laura
- Sanz, Guillermo
- Elias, Harold K.
- Smith, Alexandra G.
- Werner, Yesenia
- Neuberg, Donna S.
- Stevenson, Kristen E.
- Menghrajani, Kamal
- Bolton, Kelly L.
- Fenaux, Pierre
- Pellagatti, Andrea
- Platzbecker, Uwe
- Heuser, Michael
- Valent, Peter
- Miyazaki, Yasushi
- Finelli, Carlo
- Voso, Maria Teresa
- Shih, Lee-Yung
- Fontenay, Michaela
- Jansen, Joop H.
- Cervera, José
- Atsuta, Yoshiko
- Ebert, Benjamin L.
- Bejar, Rafael
- Greenberg, Peter L.
- Cazzola, Mario
- Ogawa, Seishi
- Papaemmanuil, Elli
- Venue
- Nature Medicine
- Published
- 2020-08-03
- Volume
- 26
- Issue
- 10
- Pages
- 1549-1556
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC8381722
- OpenAlex
- W3046671820
- Cited by
- 648
- References
- 58
- Citations by year
- 2026: 73 · 2025: 91 · 2024: 106 · 2023: 136 · 2022: 130 · 2021: 87 · 2020: 22
- FWCI
- 59.16
- Type
- journal article
- Language
- en
- Update notices
- Open access
- green
- doi.org
- Licence
- Locations
- Nature Medicine (publishedVersion)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Florence Research (University of Florence) (submittedVersion, other-oa)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, other-oa)
- eScholarship (California Digital Library) (submittedVersion)
- GoeScholar The Publication Server of the Georg-August-Universität Göttingen (Georg-August-Universität Göttingen) (submittedVersion, cc-by)
- Radboud Repository (Radboud University) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- Amgen
- Pfizer
- Sanofi
- Alexion Pharmaceuticals
- Celgene (21267)
- Helsinn
- European Hematology Association
- Japan Agency for Medical Research and Development (JP18ck0106353, 19ck0106250h0003, JP19cm0106501)
- Taiho Pharmaceutical
- TG Therapeutics
- Astex Pharmaceuticals
- Sunesis
- Incyte
- Nippon Shinyaku
- Celltrion
- Geoffrey Beene Foundation
- Cancer Research UK (29685)
- Agence Nationale de la Recherche (ANR-18-IBHU-0003)
- Ministry of Education, Culture, Sports, Science and Technology (hp160219)
- Austrian Science Fund (#F4704-B20)
- Ministero dell’Istruzione, dell’Università e della Ricerca (21267)
- Astellas Pharma
- Associazione Italiana per la Ricerca sul Cancro (21267, 5×1000, 20125, 13042, project #21267, IG #20125)
- Genesis Pharma
- Otsuka Pharmaceutical
- Ono Pharmaceutical
- Blood Cancer UK (13042)
- Chugai Pharmaceutical
- Pharmacyclics
- Sanofi K.K.
- Japan Society for the Promotion of Science (19H03684, 13042, 18H02836, 26221308, hp160219, 19H05656, 15H05909)
- National Cancer Institute (P30CA008748, K12CA184746, P50CA254838)
- Daiichi Sankyo Europe
- Cilag
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Keywords
- TP53 mutation, myelodysplastic syndrome, allelic state, monoallelic variants, biallelic variants, genome stability, leukemic transformation, acute myeloid leukemia, complex karyotype, prognosis, treatment response, wild-type p53
- MeSH terms
- Alleles, DNA Mutational Analysis, Female, Gene Frequency, Humans, Male, Mutation, Myelodysplastic Syndromes, Phenotype, Prognosis, Cohort Studies, Survival Analysis, Tumor Suppressor Protein p53, Treatment Outcome, Loss of Heterozygosity, Genomic Instability, DNA Copy Number Variations
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
